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Abstract
Background: Folate status, as reflected by red blood cell (RCF) and plasma folates (PF), is related to health and disease risk.
Folate degradation products para-aminobenzoylglutamate (pABG) and para-acetamidobenzoylglutamate (apABG) in 24
hour urine have recently been shown to correlate with blood folate.
Aim: Since blood sampling and collection of 24 hour urine are cumbersome, we investigated whether the determination of
urinary folate catabolites in fasted spot urine is a suitable non-invasive biomarker for folate status in subjects before and
during folic acid supplementation.
Study Design and Methods: Immediate effects of oral folic acid bolus intake on urinary folate catabolites were assessed in
a short-term pre-study. In the main study we included 53 healthy men. Of these, 29 were selected for a 12 week folic acid
supplementation (400 mg). Blood, 24 hour and spot urine were collected at baseline and after 6 and 12 weeks and PF, RCF,
urinary apABG and pABG were determined.
Results: Intake of a 400 mg folic acid bolus resulted in immediate increase of urinary catabolites. In the main study pABG
and apABG concentrations in spot urine correlated well with their excretion in 24 hour urine. In healthy men consuming
habitual diet, pABG showed closer correlation with PF (rs = 0.676) and RCF (rs = 0.649) than apABG (rs = 0.264, ns and 0.543).
Supplementation led to significantly increased folate in plasma and red cells as well as elevated urinary folate catabolites,
while only pABG correlated significantly with PF (rs = 0.574) after 12 weeks.
Conclusion: Quantification of folate catabolites in fasted spot urine seems suitable as a non-invasive alternative to blood or
24 hour urine analysis for evaluation of folate status in populations consuming habitual diet. In non-steady-state conditions
(folic acid supplementation) correlations between folate marker (RCF, PF, urinary catabolites) decrease due to differing
kinetics.
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Introduction
Suboptimal folate status is related to higher risks of neural tube
defects [1,2], decline of cognitive performance in dementia and
Alzheimer’s disease [3], depression [4], heart diseases, increased
homocysteine levels [5,6,7] and cancer risks [8,9]. Recently higher
folate status has been associated with growth and progression of
preexisting cancerous lesions [10,11,12,13,14], which raises
concerns in respect to excessively high folate intakes and
underscores the relevance of the determination of folate status
for the identification of increased disease risks.
Red blood cell folate (RCF) and plasma folate (PF) levels are
widely accepted direct biochemical indicators of folate status, but
determination requires blood sampling. RCF is considered as
a long term marker as the red blood cell folate pool turns over
slowly [2,15]. It represents folate stores [2,15] and is widely used as
a marker of folate status. In contrast, circulating PF changes
rapidly after folate intake [16].
Gregory et al. [17] and McPartlin et al. [18] demonstrated that
folates are catabolized in the liver to para-aminobenzoylglutamate
(pABG), which is excreted in urine predominantly after acetylation
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to para-acetamidobenzoylglutamate (apABG). Folate catabolite
excretion in urine decreases with low dietary folate intake and
increases after folate supplementation [19]. Thus, similar to RCF
and PF, the urinary folate catabolites pABG and apABG might
reflect folate status.
Only limited data are currently available comparing blood
folate contents with urinary folate catabolite excretion. Kim et al.
[20] analyzed folate catabolite excretion, blood folate status
markers and dietary folate intake and found significant correla-
tions between these markers. Wolfe et al. [19] determined blood
and urine markers in postmenopausal women on controlled diets
with deficient and adequate folate content and found a significant
correlation between the sum of pABG and apABG excretion in
urine and PF. While these findings suggest a close relationship
between blood folate and urinary catabolite excretion during low
folate intake, the correlation has not been fully investigated during
folic acid supplementation.
Wolfe et al. and Kim et al. [19,20] studied relations between
folate catabolite excretion in 24 hour urine and blood folates.
Collection of blood samples as well as 24 hour urine are
laborious, costly and invasive and 24 hour urine collection may be
impaired by loss of volume or degradation of analytes over time
[21,22]. Therefore we studied the relation between urinary folate
catabolite concentrations relative to creatinine in spot urine
samples and folate levels in plasma and red blood cells. Although
diurnal variations are averaged out by 24 hour collection, there
are still indications that daily excretion of urinary pABG and
apABG may not only be determined by long-term folate storage
but also influenced by short-term folic acid intake [23]. Thus, we
evaluated the relationship between urinary folate catabolites and
blood folate markers in healthy males before (baseline) and during
a 12 week period of folic acid supplement intake. Prior to this,
short-term effects of a folic acid bolus on urinary catabolite
concentrations were studied to evaluate limitations that have to be
observed for collection of eligible spot urine. The calculated ratio
between folate catabolites pABG and apABG (ratiop/ap) was
furthermore used to detect potentially biased spot urine.
Subjects and Methods
Study Participants
The sample size estimation was performed for the baseline
study. We aimed to detect a correlation of at least 0.35 between
urinary folate catabolites and blood folate as corresponding
correlations had been observed between various measures of
dietary folate intake and blood folate markers [24,25]. To detect
such a correlation as statistically significant with a power 80% and
a of 0.05, samples from 49 subjects have to be analyzed [26].
Thus, 53 apparently healthy men were enrolled into the baseline
study to compensate for eventually later detected exclusion criteria
(Figure 1). The subsequent 12 week intervention of 29 subjects
with an intake of 400 mg folic acid per day was accomplished
based on an explorative design without explicit power calculation.
The objectives and procedures of the study were explained and
all participants provided written informed consent. The research
protocol was approved by the Ethical Committee of the Medical
Faculty of the University of Munich and the study was registered
at clinicaltrials.gov under NCT00689949. Requirements for
inclusion into the study were no reported diagnosis of intestinal,
renal or thyroid disease, normal full blood count, no alcohol or
drug abuse (max 1 alcoholic drink per day), and no concurrent
participation in other clinical studies. Medication during the last
three month, which was assumed to interfere with folate status,
was an exclusion criterion. Test persons having a regular
consumption of vitamin supplements (including folate) were not
excluded, since we aimed to cover a wide range of folate levels.
Study Design and Sample Collection
Data were collected between May and October 2008. The
baseline study included two examinations, 21 days apart. Each
examination was arranged in the morning after $12 hours of
fasting. After discarding the first morning void urine at home, the
second fasted spontaneous urine was collected in urine containers
(70 mL, Sarstedt, Germany) at the study center (Division of
Metabolic and Nutritional Medicine, Dr. von Hauner Children’s
Hospital, Medical Center of Ludwig Maximilians University,
Munich, Germany). Directly after collection urines were centri-
fuged (20006g, 5 min) or filtered (syringe filter 25 mm, 0.2 mm
nylon membrane, VWR, Germany), then aliquoted and stored at
280uC. Previous experiments in our laboratory had shown that
folate catabolites were stable in urine for more than five days at
room temperature. (Niesser et al., submitted) At the same time
blood samples were collected in tubes containing EDTA and
heparin (EDTA-, Heparin Monovette, Sarstedt, Germany). For
determination of whole blood folate, 100 mL of heparinized, whole
blood was mixed with 900 mL fresh ascorbic acid solution (1%) for
hemolyzation in the dark (30 min) and stored at 280uC. After
centrifugation of Heparin-Monovettes (17006g, 5 min), the
plasma was aliquoted into Eppendorf tubes and stored at
280uC until analysis of PF.
24 hour urine was collected during the day and night preceding
the second examination in a light protecting urine bottle (Urisafe,
3.0 L PP, VWR, Germany) prefilled with 30 mL hydrochloric acid
(1N) for limitation of microbial growth and preservation of sample
quality. Total urine volume was recorded for each participant.
After centrifugation or filtration, urine aliquots were stored at
280uC until analysis.
From the participants of the baseline study the fifteen
participants having the lowest RCF concentration and the
fourteen subjects having the highest RCF concentration, de-
termined in the baseline study, were included in the subsequent
intervention with folic acid (intervention study) (Figure 1). They
consumed 400 mg folic acid (Folverlan, 0.4 mg, Verla-Pharm,
Germany) daily for twelve weeks. Morning spot urine and blood
samples were collected after 6 and 12 weeks of supplementation
(Figure 1).
For the investigation of urinary folate catabolite excretion
shortly after folate ingestion, a two day short-term study was
conducted, including seven apparently healthy, lean volunteers. At
day one, participants delivered urine samples four times during
a fasting period of three hours, starting with the second fasted
urine, taken in the morning after an overnight fasting period.
Urine samples two, three and four were collected one, two and
three hours after the first urine collection. Experimental conditions
on day two were identical to day one, but after collection of the
first urine sample a 400 mg folic acid tablet (Folverlan, 0.4 mg,
Verla-Pharm, Germany) was ingested.
Urine Analysis
Urine folate catabolites pABG and apABG were quantified by
high performance liquid chromatography combined with tandem
mass-spectrometry (LC-MS/MS) (Niesser et al., submitted). Brief-
ly, 80 mL urine were transferred into a well plate which was pre-
filled with acetonitrile, methanol and hydrochloric acid containing
(13C2D3)apABG (synthesized according to Sokoro et al. [27]) and
(13C5)pABG (synthesized according to Niesser et al., submitted) as
internal standards. The well plate was shaken and cooled for
protein precipitation before centrifugation. The supernatants were
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Figure 1. Flow chart of study selection process.
doi:10.1371/journal.pone.0056194.g001
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transferred into a second well plate and dried under nitrogen. For
derivatization samples were re-dissolved in 3N-butanolic hydrogen
chloride and incubated at 60uC for 10 min. Derivatization was
stopped by cooling on crushed ice, butanolic hydrogen chloride
was evaporated under nitrogen and after taking up the derivates
into methanol, water and formic acid (50:50:0.1), samples were
analyzed by LC-MS/MS (Agilent Technologies 1200SL series
HPLC system, Germany; API 4000 QTrap, AB Sciex, Germany).
Chromatography was performed on an Agilent Zorbax SB C18
column (2.1650 mm, particle size 1.8 mm, Agilent, Germany).
Atmospheric pressure chemical ionization with mass transitions
379R 120, 381R 120, 384R 120, 421R 162, 426R 165, were
used for detection of pABG, (13C2)pABG, (
13C5)pABG, apABG
and (13C2D3)apABG, respectively. Relative concentrations of
urinary folate catabolites, determined in a calibration range of 2 to
1000 nmol/L, were calculated as nmol per mmol creatinine.
Creatinine was determined by a routine assay using the
Creatinine Jaffe´ method [28] on a Cobas (Roche Diagnostics,
Germany). Urinary methylmalonic acid (MMA) was analyzed by
isotope dilution GC-MS as described by Matchar et al. [29].
Urinary MMA concentrations were normalized against creatinine
concentrations. Creatinine and MMA were analyzed at the
Institute for Clinical Chemistry, University of Munich Medical
Center.
Blood Analysis
Whole blood folate, PF and urinary folate were assessed at
TNO Innovation for Life, Zeist by a microbiological assay
according to O’Broin et al. [30] using a chloramphenicol resistant,
cyro-conserved bacterial strain of L. casei and photometric
determination of bacterial growth. The lowest calibrator concen-
tration was considered as the lower limit of quantification of folate
in the assay (PF: 2.3 nmol/L; urinary folate: 2.9 nmol/L). RCF
was calculated from whole-blood and plasma folate concentrations
and hematocrit. Analyses described below were performed at the
Institute for Clinical Chemistry, University of Munich, Medical
Center. Determination of hematocrit was done using a Sysmex
XT 1800i fluorescence flow cytometer (Sysmex, Germany).
Concentrations of homocysteine in EDTA-plasma and Vitamin
B12 in serum were determined using a fully automated competitive
chemiluminescence immunoassay on an AVIDA Centaur XP
immunoassay System (Siemens Healthcare Diagnostics, Ger-
many). Vitamin B6 was analyzed as pyridoxal-59-phosphate from
EDTA-blood using a chromatographic method (Vitamin B6
reagent kit for HPLC analysis, Chromsystems, Germany).
Criteria for Exclusion of Baseline and Intervention Study
Data
Two of the initially recruited 53 participants were excluded
from statistical analysis because of elevated liver enzymes (serum
gamma-glutamyl transpeptidase (GGT) .60 U/L [31]). For
technical reasons RCF concentrations from six participants at
the second baseline examination were not available and concen-
trations from the first examination were used instead of means.
Only the first examination was included for two participants, as
a ratiop/ap.0.7 was found at the second examination indicating
potential bias of urinary folate catabolite concentrations by folate
intake shortly before sampling (see paragraph on short-term study).
Accordingly, also the 24 hour urines of these two participants were
excluded. Data of four participants at week 6 and three at week 12
of the intervention were excluded from statistical analysis for the
same reason. One subject did not participate at the week 12
examination. Finally, 51 subjects were statistically analyzed at
baseline and 25 at weeks 6 and 12 (Figure 1).
Statistical Analysis
Means per participant were calculated as baseline concentration
for all determined blood and urine analytes from examination one
and two if valid results were available for both time points.
Quantified analytes of the baseline and intervention study (week 6
and 12) are given as medians with inter quartile range (IQR) per
analyte.
Blood folate concentration RCF and PF were used as the
reference values. For evaluation of folate catabolites concentra-
tions in 24 hour urine were correlated with those in spot urine and
both with blood folate concentrations at baseline and during
supplementation in the intervention study, respectively. As data
was not normally distributed, Spearman’s non-parametric rank
correlation was used to analyze relations of biochemical param-
eters within the baseline and intervention study. (Spearman’s rank
correlation coefficient hereinafter is abbreviated as rs.) Wilcoxon’s
rank test was applied for evaluating changes by supplementation in
the short-term study and in the intervention study. Statistical
analyses were performed with Statistica 10 (StatSoft GmbH,
Germany) and PASW Statistics 18 (IBM, USA).
Results and Discussion
Increase of Urinary Folate Catabolites after Folic Acid
Intake in the Short-term Study
Kinetic modeling of stable isotope tracer data has shown that
most of the body folate is incorporated into pools with slow
turnover, e.g. half live of around 90 days [32,33]. If urinary folate
catabolites were solely derived from slow body folate pools
[19,34,35], only slow changes of catabolite concentrations in
urine without immediate dietary effects would be expected.
However, in the short-term study we found urinary apABG and
pABG to increase significantly (p#0.05) after oral ingestion of
400 mg folic acid (Figure 2A, 2B dashed line). This increase of
urinary apABG and pABG excretion was not detectable in the
group not receiving folic acid supplements (Figure 2A, 2B black
line). A portion of ingested folic acid might have been catabolized
shortly after uptake, resulting in an increase of urinary apABG and
especially pABG.
Scott et al. [36] investigated the distribution of radiolabeled
folate in rats and found different distribution patterns among
tissues. There were fast and slow turnover pools within the body
[36], thus urinary excretion may be determined by rapid and slow
excretion rates which may explain both urinary folate catabolite
increase shortly after folate intake in the short-term study and
increased catabolite excretion after long-term supplementation.
The contribution of dietary pABG and of pABG formed by pre-
absorptive cleavage of folate to urinary pABG and apABG
excretion has been reported to be very small [37]. Rather urinary
pABG may at least partly arise from nonspecific extracellular
degradation of folates either in circulation or bladder as suggested
by Geoghegan et al. [38]. Thus, the 300% increase of urinary
pABG concentration after folic acid ingestion in the short-term
study could be mainly due to fast breakdown of folic acid. It
remains to be determined whether an increase of folate catabolite
excretion only occurs after folic acid intake or also after the intake
of polyglutamated 5-methyltetrahydofolate from food.
Urinary apABG arises from endogenous folate after breakdown
and acetylation by arylamine N-acetyltransferase I (NAT1) in the
cytosol [38,39], which explains the relatively small increase of
apABG in contrast to pABG in the short-term study. NAT1 is
widely distributed in the body including the cytoplasm of epithelial
cells [39]. Phenotypes with low or higher than normal acetylation
activity in some tissues have been reported, which result in inter-
Folate Catabolites as Biomarker for Folate Status
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personal variation of pABG acetylation [39] and may explain
inter-individual differences of fasted apABG levels and variations
of the apABG increase after the ingestion of folic acid in the short-
term study.
For the calculated ratio of pABG to apABG (ratiop/ap) a median
(IQR) value of 0.42 (0.38; 0.49) was found in non-dosed state
(Figure 2C, black line) which is similar to previous reports
[18,19,40,41]. Shortly after oral intake of folic acid the ratiop/ap
increased significantly to 1.74 (1.43; 2.36) (Figure 2C, dashed line).
Observed distributions of ratiop/ap in dosed versus non-dosed state
were compared (Figure 2D). Ratiop/ap after folic acid intake
(Figure 2D, dark grey bars) was clearly higher and showed a much
higher variability than ratiop/ap measured in non-dosed state
(Figure 2D, light grey bars). The lowest observed ratiop/ap in dosed
state was 0.65 and the highest in non-dosed state was 0.70. Thus,
immediate effects of folic acid intake increased urinary concentra-
tions of pABG much more than that of apABG, thereby altering
the ratio between both analytes. Based on this observation we
suppose a ratiop/ap above 0.7 indicated recent folic acid intake. We
therefore considered only urine samples with a ratiop/ap,0.7 as
not biased by recent folic acid intake and suitable for estimating
blood folate status.
Since folic acid ingestion showed a clear short-term influence on
apABG and particularly pABG levels, estimation of folate status
from catabolite concentrations in spot urine requires overnight
fasting periods of more than 12 hours before sampling to minimize
interference. Although first morning voids are generally recom-
mended [42], they may still be influenced by folates which were
ingested before the fasting period, therefore we generally analyzed
the second fasted morning urine, collected 1 to 2 hours after
discarding the first morning void. Spot urine collected according to
this protocol was most likely produced exclusively during periods
where no absorption of folates from the intestinal tract was
occurring, therefore mirroring folate release from body storage as
closely as possible.
Aims of Baseline and Intervention Study
The aim of our study was to evaluate the estimation of folate
status by quantifying urinary pABG and apABG, as a non-invasive
alternative to the analysis blood folate. Blood folate concentration
RCF and PF were used as the reference values, so we compared
concentrations of 24 hour urine to spot urine and both to blood
folates at baseline. During supplementation blood folate concen-
trations were only related to catabolite concentrations in spot
urine.
Study Population of Baseline and Intervention Study
In routine analysis blood and urine parameters in the reference
ranges were only found for 51 of 53 participants (data not shown),
since two participants showed elevated liver enzymes (serum GGT
.60 U/L [31]). Quantitative results of blood and urine analyses of
the baseline study are given in Table 1. Creatinine excretion per
day showed no indication of abnormal kidney function in any
Figure 2. Time course of urinary apABG and pABG after folic acid intake (short-term study). Time course (medians, error bars = inter
quartile range (IQR)) of urinary apABG (nmol/mmol creatinine) (A) and pABG (nmol/mmol creatinine) (B), in fasted state (black line) and after oral
intake of 400 mg folic acid (dashed line) during the first three hours. (C) Time course of the ratio between pABG and apABG (ratiop/ap) in spot urine
without (black) and with (dashed line) intake of folic acid at time 0. Significant differences from time point 0 are marked with an asterisk (*: p#0.05,
Wilcoxon’s test). (D) Histograms of observed frequencies of ratiop/ap in spot urine in non-dosed state (light grey bars) and 2 h after oral folate intake
(dark grey bars), displayed with continuous kernel density function estimates (black lines).
doi:10.1371/journal.pone.0056194.g002
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participant (Table 1) [22], which might have interfered with
urinary folate catabolites excretion. No correlations of age, height,
weight, body mass index (BMI), hematocrit or creatinine excretion
per day with PF or RCF were observed (Table 1).
Comparison of Folate Catabolites in 24 Hour and Spot
Urine at Baseline
To our knowledge, no studies evaluating urinary folate
catabolite concentrations in spot urine have been published so
far. Excretions in 24 hour urine have been related to blood folate
concentrations and correlations between folate catabolite excretion
and the blood folate status have been reported (r< 0.4) [19,20]. In
the present study correlations between blood folates and catabolite
excretions in 24 hour urine equaled reported relations in respect to
urinary pABG (PF: rs = 0.336, p,0.05, RCF: rs = 0.440, p,0.05,
Table 1). Also urinary apABG excretion was by trend related to
RCF (rs = 0.290, p.0.05). Furthermore spearman’s rank correla-
tion between folate catabolites concentration in spot urine and
excretion in 24 hour urine in the baseline study was 0.419
(p,0.005) for pABG, and 0.701 (p,0.001) for apABG (Figure 3A,
3B). Since correlations between blood folates and catabolite
concentrations in spot urine were stronger, than those of blood
folates and catabolite excretions in 24 hour urine (Table 1),
collection of 24 hour urine and determination of urinary
excretions per day seemed not necessary for non-invasive
evaluation of blood folate status via urinary folate catabolites.
Other authors have reported lower pABG and apABG
excretion in 24 hour urine [18,19,20,34,40,41] than the 71.2 nmol
pABG and 211 nmol apABG per day we have found. This might
be related to methodological differences, as analytical procedures,
including de-acetylation of apABG [18,19,34,41] or pre-concen-
tration of folate catabolites without internal standard [41], are
more susceptible to loss of analytes than direct analysis by LC-
MS/MS. Furthermore, habitual folate intake may be higher in our
study population than in previously studied subjects, e.g. in areas
with less common folic acid fortification of foods [43].
Daily creatinine excretion of all participants was within
previously published ranges [22] and creatinine concentrations
in 24 hour urine (mmol/L) were highly negatively correlated with
their appertaining urine volumes (rs =20.916, p,0.001). This
indicated correct and complete urine sampling, although this has
been a problem in other studies [21,22].
Relations between Blood Folates RCF and PF and Urinary
Folate Catabolites pABG and apABG at Baseline
The baseline study showed significant correlation of RCF with
PF and of both with pABG in spot urine (Figure 3C, 3E) as well as
24 hour urine (Table 1). We found a significant correlation
between apABG and RCF in spot urine, but not in urine that was
collected for 24 hours (Table 1). Kim et al. [20] recently published
close correlations of pABG in 24 hour urine with PF, and between
apABG and RCF. They concluded that pABG reflects recent
Table 1. Description of participants and biochemical parameters during habitual diet (baseline).
Collection mode Characteristic
Median (IQR) baseline
(n=51)
Correlation with PF
(nmol/L)
Correlation with RCF
(nmol/L)
Age (years) 26.5 (23.3; 30.0) 0.105 0.128
Height (m) 1.79 (1.75; 1.83) 0.044 0.001
Weight (kg) 74.0 (70.0; 86.5) 0.009 0.040
BMI 23.4 (21.5; 24.9) 0.016 0.072
Blood Folate, red blood cells (nmol/L) 731 (591; 860) 0.781** 1
Folate, plasma (nmol/L) 14.3 (11.3; 21.5) 1 0.781**
Homocysteine, plasma (mmol/L) 11.5 (10.0; 13.1) 20.420* 20.222
Vitamin B6, EDTA blood (mg/L) 25.4 (22.5; 31.3) 0.242 0.195
Vitamin B12, EDTA blood (ng/L) 439 (393; 474) 0.056 20.091
Hematokrit (%) 43.8 (42.0; 45.4) 20.022 0.079
Spot urine pABG (nmol/mmol creatinine) 3.59 (2.98; 4.32) 0.676** 0.649**
apABG (nmol/mmol creatinine) 10.9 (8.86; 12.3) 0.264 0.543**
Folate (nmol/mmol creatinine) 0.55 (0.38; 0.78) 0.540** 0.423*
MMA (mg/g creatinine){ 1.64 (1.35; 1.99) 20.216 20.196
Ratiop/ap 0.34 (0.29; 0.40) 0.349* 0.050
24 hour urine pABG (nmol/24 hour) 71.2 (58.7; 95.2) 0.336* 0.440*
apABG (nmol/24 hour) 211 (183; 263) 0.073 0.290
Folate (nmol/24 hour) 7.74 (4.17; 11.5) 0.473** 0.529**
Ratiop/ap 0.36 (0.30; 0.40) 0.335* 0.149
Creatinine (mmol/24 hour) 17.4 (15.6; 19.6) 20.087 20.029
Urine volume (mL) 1720 (1380; 2380) 0.058 0.042
Values are given as median, IQR in parentheses. Results of the two baseline measurements were averaged, if valid data were available from both examinations. Relations
between variables were analyzed by Spearman’s rank correlation. Significance level:
*p,0.05,
**p,0.001. pABG: para-aminobenzoylglutamate, apABG: para-acetamidobenzoylglutamate, MMA: methylmalonic acid, ratiop/ap: ratio of pABG to apABG.
{One extreme outlier was excluded.
doi:10.1371/journal.pone.0056194.t001
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folate intake, whereas apABG accounts for whole body folate.
Wolfe et al. [19] correlated the sum of pABG and apABG, as ‘total
pABG’, with blood folates and found a slightly higher correlation
with RCF than with PF. In both studies urinary apABG was
reported as the more abundant folate catabolite [19,20]. We also
found higher concentrations in spot urine and higher excretions in
24 hour urine of apABG than of pABG (Table 1), which
confirmed apABG as the main urinary folate catabolite, at least
during fasting. Nevertheless, RCF correlated closer with pABG
than with apABG and PF only showed non-significant correlations
(rs ,0.3, p.0.05) with apABG concentrations in spot and 24 hour
urine. In contrast, pABG in spot as well as 24 hour urine
correlated significantly with PF. This is in line with the assumption
that fast turnover pools are well reflected by urinary pABG, while
a closer relationship of slower turnover pools to apABG than to
pABG could not be confirmed.
Intervention Study: 12– Week Oral Supplementation with
Folic Acid
Caudill et al. [41] found non-significantly higher urinary pABG
excretion in non-pregnant women consuming 850 mg folate per
day (mainly synthetic folic acid) than in women consuming
450 mg. We found highly significant increases of pABG (p#0.001,
Figure 4C) and apABG concentrations in spot urine (p#0.001,
Figure 4D) from baseline with habitual folate intake to week 6 and
Figure 3. Correlation of folate catabolites in spot urine with 24 hour urine and blood folate concentrations. Comparison of folate
catabolites in spot urine and 24 hour urine. Creatinine normalized concentration of para-aminobenzoylglutamate (pABG) (A) and para-
acetamidobenzoylglutamate (apABG) (B) in spot urine is correlated with daily excretion in 24 hour urine. Correlations of urinary pABG with plasma
and red blood cell folate, a comparison between baseline and week 12. Scatterplots for para-aminobenzoylglutamate (pABG)/creatinine in spot
urine related to plasma folate and red blood cell folate concentrations, at baseline (C, E, n = 51) and week 12 (D, F, n = 25). For ease of comparison,
dashed lines in C, D, E and F indicate the lowest value of the respective biomarker at week 12.
doi:10.1371/journal.pone.0056194.g003
Folate Catabolites as Biomarker for Folate Status
PLOS ONE | www.plosone.org 7 February 2013 | Volume 8 | Issue 2 | e56194
week 12 of supplementation in subjects supplementing 400 mg folic
acid per day in addition. This is in agreement with data reported
by Wolfe et al. [19], who only found significantly higher total
pABG (sum of pABG and apABG) excretion after increasing daily
folate intake for 7 weeks from 115 mg (depleted diet) to 400 mg per
day.
Folic acid supplementation in the intervention study resulted in
significant increases of RCF (p = 0.005, Figure 4B) and PF
(p#0.001, Figure 4A) from baseline to week 6. RCF increase
during the first 6 weeks was significant, but lower than the increase
between week 6 and week 12 (Figure 4B). Given this pattern of
longitudinal change, a 12 week supplementation period with
400 mg folic acid seemed not sufficient to achieve a steady state of
RCF concentrations as also reported by Houghton et al. [44].
PF can rapidly be influenced by dietary folate intake [45]. In
our study PF increased mostly during the first 6 weeks of folic acid
supplementation and less steeply from week 6 to week 12.
Similarly, Hao et al. [46] observed a plateau for PF after 12 weeks
of supplementation with 400 mg folic acid/d in young women.
Folic Acid Supplementation Induced Changes of
Correlations
The relationship between blood folates and urinary folate
catabolite concentrations during folic acid supplementation in the
intervention study was different from that observed at baseline
(Figure 3D and 3F; Table 2). The correlation between RCF and
pABG, still highly significant at baseline (rs = 0.649, p,0.001),
vanished during supplementation at week 6 (rs = 0.074, p.0.05)
and week 12 (rs = 0.097, p.0.05). The relationship between RCF
and apABG was also stronger at baseline (rs = 0.543, p,0.001),
but did not completely disappear during supplementation (week 6:
rs = 0.228, week 12: rs = 0.343). The most stable association was
observed between PF and pABG in spot urine, which was also
highest at baseline (rs = 0.676, p,0.001) and remained visible
during folic acid treatment (week 6: rs = 0.346, p.0.05, week 12:
rs = 0.574, p,0.05). In contrast, no significant correlation between
PF and apABG was observed during intervention. Correspond-
ingly, Wolfe et al. [19] reported significant correlations of serum
folate and RCF with the sum of pABG and apABG excretion at
study start and after 7 weeks of folate depletion, but did not find
significant correlation after oral dosage of 400 mg/day for further
7 weeks.
In our short-term study, a 400 mg oral bolus of folic acid
substantially affected urinary catabolite concentrations. Previously,
Prinz-Langenohl et al. [16] had shown that intake of 400 mg folic
increased PF for a prolonged time period. Although it has been
suggested that pABG partially originates from nonspecific
extracellular folic acid degradation in the circulation [38],
concentration variations in plasma and urine may follow different
time courses and PF and urinary pABG may be differently biased
Figure 4. Time course of plasma, red blood cell folate, urinary pABG and apABG during folic acid supplementation. Time course of
the median concentrations (error bars = inter quartile range (IQR)) of plasma folate (nmol/L) (A), red blood cell folate (nmol/L) (B), pABG (nmol/mmol
creatinine) (C) and apABG (nmol/mmol creatinine) (D) during folic acid supplementation. Significant changes from baseline: *: p = 0.005 and **:
p#0.001 (Wilcoxon’s test).
doi:10.1371/journal.pone.0056194.g004
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by recent folate intake, depending on the timing of the last folic
acid intake. The correlation between PF and pABG may have
been attenuated further by excluding urine samples with a ratiop/
ap above 0.7, since these samples exhibited both exceptionally high
values for PF and pABG.
It has been shown in postmenopausal women that RCF has
a delayed and attenuated response to periods of folate depletion
and repletion when compared to PF [47], while urinary pABG
and apABG excretion only showed non-significant trends to
change in response to the controlled variations of folic acid intake
[34,47]. This agrees with the assumption of kinetically different
folate pools derived from tracer studies [32]. Thus, higher short-
term variations of PF and catabolite concentrations in urine during
supplementation than at baseline and the existence of several
folate pools with different kinetic behavior may well explain the
absence of significant correlations between plasma and urine
markers after 6 weeks of supplementation. After 12 weeks of folic
acid intake the correlation between PF and urinary pABG was
similar to the correlation at baseline, which confirms that both
parameters reflect fast changing pools [20]. Furthermore, diurnal
variations of PF and pABG might have become less pronounced
after 6 more weeks on constantly elevated folic acid intake. On the
other hand the quantitatively major folate catabolite apABG did
not correlate with PF and RCF and one might infer from this that
apABG is mainly derived from other, probably cellular, pools [48].
Furthermore, this finding would be consistent with the assumption
that the red cell folate pool followed different kinetics than tissue
folate pools, which has been shown in rats [36] but not studied in
humans so far. It is of importance to note that different turnover of
folate in red cells and major folate containing tissues such as liver,
does not contradict with the well proven suitability of RCF to
indicate body folate status in steady state.
In contrast to previous studies [19,37,41], we did not collect 24
hour urine during supplementation, because we assumed 24 hour
excretion would not be more closely related to PF or RCF than
fasted, second void morning urines, unless the subjects followed
precisely a time schedule defining folic acid intake, start of
collection period and blood sampling.
Thus, recent onset of bolus doses of folic acid in subjects with
relatively low folate status seems to preclude reliable estimation of
RCF from urinary folate catabolites, but the situation may be
different after periods of more than 3 months of continuous
supplement intake.
Urinary Folate, Homocysteine and B- Vitamins
The very small urinary folate excretion per day in the baseline
study was consistent with previous findings [32,41]. Although
folate excretion increased significantly with oral folic acid
supplementation, the sum of urinary pABG and apABG exceeded
urinary folate, as already shown by Gregory et al. [23,35]. PF and
RCF concentration were significantly correlated to urinary folate
in spot urine and 24 hour urine at baseline (Table 1). After 12
week of folic acid supplementation, PF correlated with urinary
folate in spot urine (rs = 0.420, p,0.05). Compared to urinary
folate catabolites, measuring urine folate for estimation of folate
status has several important disadvantages: Urinary folates are
much less stable than folate catabolites [49] and therefore
determination in large-scale studies is likely to be severely biased
by sampling conditions. Urinary folates are also much more
influenced by immediate dietary intake of folates [50] warranting
very strict control of sample timing. On the other hand, folate
catabolites, namely apABG, are better correlated to mid-term
folate storage pools (RBC folate, tissue folate [32], in contrast to
urinary folate which follows short-term variations in plasma folate.
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82.4% of all participants had homocysteine levels lower than
15 mmol/L, which is recommended for adults [6,7]. Only one
participant showed a homocysteine level above 30 mmol/L, which
indicated hyperhomocysteinemia [6]. While significant negative
correlation (rs =20.420; p,0.001) between PF and homocysteine
was found, there was no significant correlation between RCF and
homocysteine in plasma at baseline. As observed previously [51],
homocysteine levels decreased significantly (p,0.05) during
supplementation (Table 2). Wald et al. [51] reported lately that
the higher a subject’s initial homocysteine level, the larger it’s
decrease in response to folic acid supplementation. According to
that we also detected slightly higher response to the 12 week daily
folic acid intake in a subgroup with elevated homocysteine levels at
baseline (homocysteine .15 mmol/L), while subjects with normal
baseline values (,15 mmol/L) exhibited only minor changes of
plasma homocysteine during intervention. As Lobo et al. [52]
already observed in a group taking 400 mg folic acid per day,
decrease of homocysteine levels directly after starting supplemen-
tation in our subjects was higher (p,0.05) than those between
week 6 and 12 of daily folic acid intake (Table 2). But maintained
supplementation up to 12 weeks furthermore increased the
significance of chances (p,0.005) compared to baseline levels.
Measurements of pyridoxal phosphate, cobalamin and urinary
methylmalonic acid provided no indication of vitamin B6 or B12
deficiency in any of the participants [29,53]. Since no significant
correlations between vitamins B6 and B12 and blood and urine
based markers of folate status were detected, we assumed that
these vitamins did not influence the relationship between folate
status markers.
Limitations of the Study
A major shortcoming of the current study, which only studied
well-nourished Europeans (Germans), was that none of the
subjects exhibited clearly in-adequate folate status, i.e. all
individuals had RBC folate concentrations .400 nmol/L. Due
to this limitation, we were not able to determine cut-of values of
urinary folate catabolites indicating inadequate folate status.
Further investigations in populations with insufficient folate
intake might provide information for determining such cut-off
points.
The inclusion of healthy middle-aged men only, which
somewhat limits generalizability of results, was guided by the
intention of providing the most homogenous study population for
systematically addressing baseline variation and intervention
effects. Including women might have led to a more inhomoge-
neous group (due to folate-containing oral contraceptives [54],
pregnancy or lactation [55]) and studying children seemed
ethically inappropriate.
Using LC-MS/MS for analysis of folate catabolites might seem
to limit availability of the proposed assay to specialized laborato-
ries, but this technology stands out in delivering an unprecedented
combination of sensitivity and selectivity with relatively low costs
per sample. Furthermore, LC-MS/MS has become more and
more widely available in recent years, since it has already been
introduced into routine laboratories [56].
Conclusions
Our results in non-folic acid supplemented subjects show that
urinary pABG normalized to creatinine in spot urine is more
closely related to PF than apABG whereas urinary concentrations
of both folate catabolites showed comparable correlations with
RCF. This suggests that pABG/creatinine in spot urine is suitable
as a non-invasive biomarker for folate status. A fasting period of
more than 12 hours before sampling of the second fasted morning
spot urine is recommended to exclude overestimation of folate
status due to recent folate intake. The property of folate catabolites
to be stable at ambient temperature in urine samples for several
days makes collection of urine samples an attractive choice for
non-invasive field studies. In general, measuring folate catabolites
instead of folates involves much less variation due to sampling and
measurement errors since folate catabolites do not share the well-
known chemical instability of folate species. The ratio of pABG to
apABG in urine appears to be a suitable marker of sampling
conditions compliance. This ratio is rapidly increased by oral
intake of folates enabling identification and exclusion of biased
urine samples not suitable for reliable estimation of folate status.
Folic acid supplementation up to 12 weeks attenuates correlations
between urinary and blood folate markers. Thus, only the fast
adapting folate compartment PF can be probed non-invasively
during supplementation by pABG determination in urine while
RCF and apABG seem to reflect different slowly adapting pools.
Our results suggest further investigation of the relationship
between folate status-related disease risks and pABG and apABG
in spot urine of subjects with habitual folate intake, since it
potentially may replace invasive blood sampling as well as error-
prone 24 hour urine collection in medical diagnosis and clinical
trials.
Supporting Information
Document S1 Study Protocol: ‘‘Determination of the
suitability of urinary total p-aminobenzoyglutamate and
formiminoglutamate as a markers for folate status’’.
(PDF)
Document S2 Funding Sources.
(PDF)
Document S3 CONSORT Checklist.
(PDF)
Acknowledgments
The presented data is part of a PhD thesis accomplished by Mareile Niesser
at the Medical Faculty of the Ludwig Maximilians University of Munich.
Author Contributions
Conceived and designed the experiments: HD DM ARP BK WP.
Performed the experiments: MN TW MvL WV WP. Analyzed the data:
MN WP. Wrote the paper: MN HD BK WP.
References
1. Molloy AM, Kirke PN, Brody LC, Scott JM, Mills JL (2008) Effects of folate and
vitamin B12 deficiencies during pregnancy on fetal, infant, and child
development. Food Nutr Bull 29: S101–111; discussion S112–105.
2. Daly LE, Kirke PN, Molloy A, Weir DG, Scott JM (1995) Folate levels and
neural tube defects. Implications for prevention. JAMA 274: 1698–1702.
3. Hooshmand B, Solomon A, Kareholt I, Rusanen M, Hanninen T, et al. (2012)
Associations between serum homocysteine, holotranscobalamin, folate and
cognition in the elderly: a longitudinal study. J Intern Med 271: 204–212.
4. Seppala J, Koponen H, Kautiainen H, Eriksson JG, Kampman O, et al. (2012)
Association between folate intake and melancholic depressive symptoms. A
Finnish population-based study. J Affect Disord 138: 473–478.
5. Veeranna V, Zalawadiya SK, Niraj A, Pradhan J, Ference B, et al. (2011)
Homocysteine and reclassification of cardiovascular disease risk. J Am Coll
Cardiol 58: 1025–1033.
6. Refsum H, Ueland PM, Nygard O, Vollset SE (1998) Homocysteine and
cardiovascular disease. Annu Rev Med 49: 31–62.
Folate Catabolites as Biomarker for Folate Status
PLOS ONE | www.plosone.org 10 February 2013 | Volume 8 | Issue 2 | e56194
7. Herrmann M, Taban-Shomal O, Hubner U, Bohm M, Herrmann W (2006) A
review of homocysteine and heart failure. Eur J Heart Fail 8: 571–576.
8. Kim YI (2007) Folate and colorectal cancer: an evidence-based critical review.
Mol Nutr Food Res 51: 267–292.
9. Prinz-Langenohl R, Fohr I, Pietrzik K (2001) Beneficial role for folate in the
prevention of colorectal and breast cancer. Eur J Nutr 40: 98–105.
10. Ericson U, Borgquist S, Ivarsson MI, Sonestedt E, Gullberg B, et al. (2010)
Plasma folate concentrations are positively associated with risk of estrogen
receptor beta negative breast cancer in a Swedish nested case control study.
J Nutr 140: 1661–1668.
11. Ebbing M, Bonaa KH, Nygard O, Arnesen E, Ueland PM, et al. (2009) Cancer
incidence and mortality after treatment with folic acid and vitamin B12. JAMA
302: 2119–2126.
12. Chuang S-C, Stolzenberg-Solomon R, Ueland PM, Vollset SE, Midttun Ø, et
al. (2011) A U-shaped relationship between plasma folate and pancreatic cancer
risk in the European Prospective Investigation into Cancer and Nutrition.
European Journal of Cancer 47: 1808–1816.
13. Smith AD, Kim YI, Refsum H (2008) Is folic acid good for everyone? Am J Clin
Nutr 87: 517–533.
14. Tomaszewski JJ, Cummings JL, Parwani AV, Dhir R, Mason JB, et al. (2011)
Increased cancer cell proliferation in prostate cancer patients with high levels of
serum folate. Prostate 71: 1287–1293.
15. Pietrzik K, Lamers Y, Bramswig S, Prinz-Langenohl R (2007) Calculation of red
blood cell folate steady state conditions and elimination kinetics after daily
supplementation with various folate forms and doses in women of childbearing
age. Am J Clin Nutr 86: 1414–1419.
16. Prinz-Langenohl R, Bronstrup A, Thorand B, Hages M, Pietrzik K (1999)
Availability of food folate in humans. J Nutr 129: 913–916.
17. Gregory JF, Toth JP (1988) Chemical synthesis of deuterated folate
monoglutamate and in vivo assessment of urinary excretion of deuterated
folates in man. Analytical Biochemistry 170: 94–104.
18. McPartlin J, Courtney G, McNulty H, Weir D, Scott J (1992) The quantitative
analysis of endogenous folate catabolites in human urine. Anal Biochem 206:
256–261.
19. Wolfe JM, Bailey LB, Herrlinger-Garcia K, Theriaque DW, Gregory JF III, et
al. (2003) Folate catabolite excretion is responsive to changes in dietary folate
intake in elderly women. Am J Clin Nutr 77: 919–923.
20. Kim HA, Lim HS (2008) Dietary folate intake, blood folate status, and urinary
folate catabolite excretion in Korean women of childbearing age. J Nutr Sci
Vitaminol (Tokyo) 54: 291–297.
21. Mann SJ, Gerber LM (2010) Estimation of 24-hour sodium excretion from spot
urine samples. J Clin Hypertens (Greenwich) 12: 174–180.
22. Harris SA, Purdham JT, Corey PN, Sass-Kortsak AM (2000) An evaluation of
24-hour urinary creatinine excretion for use in identification of incomplete urine
collections and adjustment of absorbed dose of pesticides. AIHAJ 61: 649–657.
23. Mo¨nch S, Netzel M, Netzel G, Rychlik M (2010) Quantitation of folates and
their catabolites in blood plasma, erythrocytes, and urine by stable isotope
dilution assays. Anal Biochem 398: 150–160.
24. Park JY, Vollset SE, Melse-Boonstra A, Chajes V, Ueland PM, et al. (2012)
Dietary intake and biological measurement of folate: A qualitative review of
validation studies. Molecular nutrition & food research.
25. Verkleij-Hagoort AC, de Vries JH, Stegers MP, Lindemans J, Ursem NT, et al.
(2007) Validation of the assessment of folate and vitamin B12 intake in women of
reproductive age: the method of triads. European journal of clinical nutrition 61:
610–615.
26. Uitenbroek DG (1997) Calculate Binomial probabilities. SISA. pp. Binominal
Descriptions.
27. Sokoro AA, Etter ML, Lepage J, Weist B, Eichhorst J, et al. (2006) Simple
method for the quantitative analysis of endogenous folate catabolites p-
aminobenzoylglutamate (pABG) and its acetamido (apABG) derivative in
human serum and urine by liquid chromatography-tandem mass spectrometry.
J Chromatogr B Analyt Technol Biomed Life Sci 832: 9–16.
28. Bartels H, Bohmer M, Heierli C (1972) Serum creatinine determination without
protein precipitation. Clinica chimica acta; international journal of clinical
chemistry 37: 193–197.
29. Matchar DB, Feussner JR, Millington DS, Wilkinson RH Jr, Watson DJ, et al.
(1987) Isotope-dilution assay for urinary methylmalonic acid in the diagnosis of
vitamin B12 deficiency. A prospective clinical evaluation. Ann Intern Med 106:
707–710.
30. O’Broin S, Kelleher B (1992) Microbiological assay on microtitre plates of folate
in serum and red cells. J Clin Pathol 45: 344–347.
31. Bozbas H, Yildirir A, Karacaglar E, Demir O, Ulus T, et al. (2011) Increased
serum gamma-glutamyltransferase activity in patients with metabolic syndrome.
Turk Kardiyol Dern Ars 39: 122–128.
32. Stites TE, Bailey LB, Scott KC, Toth JP, Fisher WP, et al. (1997) Kinetic
modeling of folate metabolism through use of chronic administration of
deuterium-labeled folic acid in men. Am J Clin Nutr 65: 53–60.
33. Gregory JF III, Quinlivan EP (2002) In vivo kinetics of folate metabolism. Annu
Rev Nutr 22: 199–220.
34. Gregory JF III, Swendseid ME, Jacob RA (2000) Urinary excretion of folate
catabolites responds to changes in folate intake more slowly than plasma folate
and homocysteine concentrations and lymphocyte DNA methylation in
postmenopausal women. J Nutr 130: 2949–2952.
35. Gregory JF III, Williamson J, Liao JF, Bailey LB, Toth JP (1998) Kinetic model
of folate metabolism in nonpregnant women consuming [2H2]folic acid: isotopic
labeling of urinary folate and the catabolite para-acetamidobenzoylglutamate
indicates slow, intake-dependent, turnover of folate pools. J Nutr 128: 1896–
1906.
36. Scott KC, Gregory JF III (1996) The fate of [3H]folic acid in folate-adequate
rats. The Journal of Nutritional Biochemistry 7: 261–269.
37. Caudill MA, Bailey LB, Gregory JF III (2002) Consumption of the folate
breakdown product para-aminobenzoylglutamate contributes minimally to
urinary folate catabolite excretion in humans: investigation using [(13)C(5)]pa-
ra-aminobenzoylglutamate. J Nutr 132: 2613–2616.
38. Geoghegan FL, McPartlin JM, Weir DG, Scott JM (1995) Para-acetamido-
benzoylglutamate is a suitable indicator of folate catabolism in rats. J Nutr 125:
2563–2570.
39. Minchin RF, Hanna PE, Dupret JM, Wagner CR, Rodrigues-Lima F, et al.
(2007) Arylamine N-acetyltransferase I. Int J Biochem Cell Biol 39: 1999–2005.
40. Alvarez-Sanchez B, Priego-Capote F, Mata-Granados JM, Luque de Castro MD
(2010) Automated determination of folate catabolites in human biofluids (urine,
breast milk and serum) by on-line SPE-HILIC-MS/MS. J Chromatogr A.
41. Caudill MA, Gregory JF, Hutson AD, Bailey LB (1998) Folate catabolism in
pregnant and nonpregnant women with controlled folate intakes. J Nutr 128:
204–208.
42. Witte EC, Lambers Heerspink HJ, de Zeeuw D, Bakker SJ, de Jong PE, et al.
(2009) First morning voids are more reliable than spot urine samples to assess
microalbuminuria. J Am Soc Nephrol 20: 436–443.
43. Crider KS, Bailey LB, Berry RJ (2011) Folic acid food fortification-its history,
effect, concerns, and future directions. Nutrients 3: 370–384.
44. Houghton LA, Gray AR, Rose MC, Miller JC, Hurthouse NA, et al. (2011)
Long-term effect of low-dose folic acid intake: potential effect of mandatory
fortification on the prevention of neural tube defects. Am J Clin Nutr 94: 136–
141.
45. Shane B (2001) Folate Chemistry And Metabolism. Clinical Research and
Regulatory Affairs 18: 137–159.
46. Hao L, Yang QH, Li Z, Bailey LB, Zhu JH, et al. (2008) Folate status and
homocysteine response to folic acid doses and withdrawal among young Chinese
women in a large-scale randomized double-blind trial. Am J Clin Nutr 88: 448–
457.
47. Jacob RA, Gretz DM, Taylor PC, James SJ, Pogribny IP, et al. (1998) Moderate
folate depletion increases plasma homocysteine and decreases lymphocyte DNA
methylation in postmenopausal women. J Nutr 128: 1204–1212.
48. Gregory JF III, Caudill MA, Opalko FJ, Bailey LB (2001) Kinetics of folate
turnover in pregnant women (second trimester) and nonpregnant controls during
folic acid supplementation: stable-isotopic labeling of plasma folate, urinary
folate and folate catabolites shows subtle effects of pregnancy on turnover of
folate pools. J Nutr 131: 1928–1937.
49. Hannisdal R, Gislefoss RE, Grimsrud TK, Hustad S, Morkrid L, et al. (2010)
Analytical recovery of folate and its degradation products in human serum
stored at 225 degrees C for up to 29 years. J Nutr 140: 522–526.
50. Kownacki-Brown PA, Wang C, Bailey LB, Toth JP, Gregory JF III (1993)
Urinary excretion of deuterium-labeled folate and the metabolite p-aminoben-
zoylglutamate in humans. J Nutr 123: 1101–1108.
51. Wald DS, Bishop L, Wald NJ, Law M, Hennessy E, et al. (2001) Randomized
trial of folic acid supplementation and serum homocysteine levels. Arch Intern
Med 161: 695–700.
52. Lobo A, Naso A, Arheart K, Kruger WD, Abou-Ghazala T, et al. (1999)
Reduction of homocysteine levels in coronary artery disease by low-dose folic
acid combined with vitamins B6 and B12. The American journal of cardiology
83: 821–825.
53. McKay DL, Perrone G, Rasmussen H, Dallal G, Blumberg JB (2000)
Multivitamin/mineral supplementation improves plasma B-vitamin status and
homocysteine concentration in healthy older adults consuming a folate-fortified
diet. J Nutr 130: 3090–3096.
54. Bart S Sr, Marr J, Diefenbach K, Trummer D, Sampson-Landers C (2012)
Folate status and homocysteine levels during a 24-week oral administration of
a folate-containing oral contraceptive: a randomized, double-blind, active-
controlled, parallel-group, US-based multicenter study. Contraception 85: 42–
50.
55. West AA, Yan J, Perry CA, Jiang X, Malysheva OV, et al. (2012) Folate-status
response to a controlled folate intake in nonpregnant, pregnant, and lactating
women. The American journal of clinical nutrition 96: 789–800.
56. Schulze A, Lindner M, Kohlmuller D, Olgemoller K, Mayatepek E, et al. (2003)
Expanded newborn screening for inborn errors of metabolism by electrospray
ionization-tandem mass spectrometry: results, outcome, and implications.
Pediatrics 111: 1399–1406.
Folate Catabolites as Biomarker for Folate Status
PLOS ONE | www.plosone.org 11 February 2013 | Volume 8 | Issue 2 | e56194
